262 related articles for article (PubMed ID: 16280863)
1. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
2. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
5. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
6. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy and prognostic factors.
Fumagalli LA; Brivio F
J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
[No Abstract] [Full Text] [Related]
8. Immunotherapy for metastatic renal cell carcinoma.
McDermott DF; Rini BI
BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
[No Abstract] [Full Text] [Related]
9. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Novara G
Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
[No Abstract] [Full Text] [Related]
10. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
Porta C
Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
[TBL] [Abstract][Full Text] [Related]
11. Decline of met-enkephalins concentration after interleukin-2 subcutaneous administration due to renal carcinoma.
Zubelewicz B; Braczkowski R; Romanowski W; Plaza J
J Exp Clin Cancer Res; 2000 Mar; 19(1):53-5. PubMed ID: 10840936
[TBL] [Abstract][Full Text] [Related]
12. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen.
Huland E; Heinzer H
Br J Cancer; 2000 Jan; 82(1):246-7. PubMed ID: 10638997
[No Abstract] [Full Text] [Related]
13. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
14. Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000.
Meyers FJ; O' Donnell RT
Clin Cancer Res; 2000 Oct; 6(10):4167. PubMed ID: 11051273
[No Abstract] [Full Text] [Related]
15. High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis.
Brusky JP; Gailani F; Pathak A; Patel H; Aboseif S
BJU Int; 2006 Feb; 97(2):279-80. PubMed ID: 16430629
[TBL] [Abstract][Full Text] [Related]
16. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
17. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
18. [Influence of immunological parameters on the effectiveness of systemic and loco-regional immunotherapy in disseminated renal carcinoma].
Granov AM; Molchanov OE; Karelin MI; Shkol'nik MI; Krotova OA
Vopr Onkol; 2009; 55(5):580-5. PubMed ID: 20020653
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
McDermott DF; Regan MM; Atkins MB
Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
